Group 1 - Bank of America downgraded Centene's rating from "Neutral" to "Underperform" with a target price cut from $52 to $30 due to concerns over the impact of the recently signed "Big Beautiful Law" by President Trump [1] - The downgrade is attributed to expected slow growth in the Medicaid market and the potential expiration of exchange subsidies this year, which poses dual pressures on Centene [1] - Analyst Joanna Gajuk indicated that significant changes in risk pools are expected to lead to more downside than upside in exchange pricing risks by 2026, with adverse effects on Medicaid enrollment starting to manifest from 2027 [1] Group 2 - HCA Healthcare's rating was downgraded from "Buy" to "Neutral," with a slight target price adjustment from $410 to $394, as funding cuts from the ACA and Medicaid are anticipated to create headwinds [1] - The decline in insured individuals may result in slower growth in hospital visits and increased bad debt, although HCA is expected to be less affected than peers due to its scale advantages [2] - The law significantly raises the likelihood of the expiration of enhanced exchange subsidies, which is expected to create additional resistance in 2026 [2]

RADNOR, Pa., July 16, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against Centene Corporation (“Centene”) (NYSE: CNC) on behalf of those who purchased or otherwise acquired Centene securities between December 12, 2024, and June 30, 2025, inclusive (the “Class Period”). The lead plaintiff deadline is September 8, 2025. ...

Core Viewpoint - Centene Corporation is facing a class action lawsuit due to allegations of providing misleading statements regarding its enrollment and morbidity rates, which led to a significant decline in its stock price after the company withdrew its 2025 guidance [3][4]. Summary by Sections Allegations - The complaint alleges that Centene's management made overwhelmingly positive statements while concealing material adverse facts about the company's true state of enrollment and morbidity rates [3]. - On July 1, 2025, Centene issued a press release withdrawing its 2025 guidance, revealing that its market growth across 22 states was lower than expected, leading to a revised guidance of approximately $1.8 billion and an adjusted diluted EPS of $2.75 [3]. - Following this announcement, Centene's stock price plummeted from $56.65 per share on July 1, 2025, to $33.78 per share on July 2, 2025, marking a decline of 40.4% [3]. Class Action Details - The class period for the lawsuit is defined as December 12, 2024, to June 30, 2025 [3]. - Shareholders are encouraged to register for the class action by September 8, 2025, to potentially be appointed as lead plaintiffs [4]. - Participants will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle [4]. Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

Group 1: Maternity Healthcare Challenges - In Illinois, 34.3% of counties are classified as maternity healthcare deserts, requiring residents to travel between 47 and 59 miles to reach a birthing hospital [1] - Many rural hospitals in Illinois have closed their labor and delivery units, exacerbating the issue of maternity care deserts [3] Group 2: OSF OnCall Connect Program - The OSF OnCall Connect program aims to provide pregnancy and postpartum care to women on Medicaid in Central Illinois, particularly in underserved counties [2][3] - The program includes a mobile clinic that will offer prenatal and postpartum services, including sonograms, lab work, vaccinations, and blood pressure monitoring [1][3] Group 3: Operational Details - The mobile unit is set to begin operations in July 2025, with eligible patients able to self-enroll or be referred by their healthcare provider [3] - The OSF OnCall Connect team will assist with program enrollment and scheduling appointments for the mobile clinic [3] Group 4: Services Offered - Services provided by the mobile clinic include education and information for each week of pregnancy, regular check-ins, 24/7 virtual access to a care team, blood pressure monitoring, lab work, screening for postpartum depression, and breastfeeding support [8]

Core Viewpoint - A lawsuit has been filed against Centene Corporation and its senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2]. Company Overview - Centene Corporation is a healthcare company that provides services to consumers enrolled in government-sponsored healthcare programs such as Medicaid and Medicare, as well as those purchasing insurance under the Affordable Care Act [3]. Financial Guidance and Performance - On December 12, 2024, Centene announced financial guidance for fiscal year 2025, claiming stability in earnings despite challenges [4]. - The company increased its 2025 guidance on February 4, 2025, citing enrollment overperformance, and again on April 25, 2025, due to strong growth in enrollment and retention [4]. - However, the actual market conditions showed lower than expected enrollment growth and increased morbidity rates in the majority of the states Centene serves [4]. Stock Market Reaction - On July 1, 2025, Centene withdrew its previous guidance after an independent actuarial report revealed lower than expected market growth and higher morbidity rates, leading to a significant stock price drop of $22.87 per share, or over 40%, from $56.65 to $33.78 [5].

Core Viewpoint - A class action lawsuit has been filed against Centene Corporation for allegedly misleading investors regarding its revenue outlook and growth projections during the Class Period from December 12, 2024, to June 30, 2025 [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals and entities that purchased Centene securities during the specified Class Period [1]. - Investors have until September 8, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit [1]. Group 2: Allegations Against Centene - The complaint alleges that Centene created a false impression of having reliable information about its projected revenue and growth while promoting high enrollment rates and low morbidity [3]. - On July 1, 2025, Centene withdrew its 2025 guidance, revealing that its market growth across 22 states was lower than expected, leading to a revised guidance of approximately $1.8 billion and an adjusted diluted EPS of $2.75 [4]. - Following this announcement, Centene's stock price plummeted from $56.65 per share to $44.78 per share, marking a decline of over 40% [4].

Core Viewpoint - A class action lawsuit has been filed against Centene Corporation for allegedly providing misleading information regarding its expected revenue and earnings during the Class Period from December 12, 2024, to June 30, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Centene's management provided investors with overly positive statements about enrollment and morbidity rates while concealing adverse facts about the company's true performance [5]. - Investors who purchased Centene common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Legal Process - Interested investors can join the class action by submitting a form or contacting the Rosen Law Firm for more information [3][6]. - A lead plaintiff must be appointed by September 8, 2025, to represent the class in the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [4]. - The firm has consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions for investors [4].

Core Viewpoint - A class action lawsuit has been filed against Centene Corporation for allegedly misleading investors about its business prospects and financial guidance [1][2]. Allegations - The complaint claims that Centene's management created a false impression of reliable information regarding projected revenue and growth, while actual enrollment rates and morbidity were lower than expected [2]. - A preliminary analysis indicated that over two-thirds of Centene's marketplace share showed disappointing enrollment and increased morbidity, contradicting the company's optimistic reports [2]. Financial Impact - On July 1, 2025, Centene withdrew its 2025 guidance, stating that market growth across 22 states was lower than anticipated, leading to a revised guidance of approximately $1.8 billion and an adjusted diluted EPS of $2.75 [3]. - Following this announcement, Centene's stock price plummeted from $56.65 per share to $44.78 per share, marking a decline of over 40% in just one day [3].

SAN DIEGO, July 15, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that the Centene class action lawsuit – captioned Lunstrum v. Centene Corporation, No. 25-cv-05659 (S.D.N.Y.) – seeks to represent purchasers or acquirers of Centene Corporation (NYSE: CNC) securities and charges Centene as well as certain of Centene’s executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the Centene cl ...

Core Viewpoint - DJS Law Group is investigating Centene Corporation for potential violations of securities laws following a significant drop in its stock price after the company withdrew its financial guidance for 2025, indicating earnings would fall short of expectations [1]. Investigation Details - The investigation centers on whether Centene made misleading statements or failed to disclose critical information to investors [1]. - Following the announcement, Centene's shares plummeted by 36.6% in morning trading on July 2, 2025 [1]. Company Background - Centene Corporation is identified as a managed-care giant, indicating its significant role in the healthcare sector [1].